SCNX

Scienture Holdings Inc. Common Stock (SCNX)

Stock · NASDAQ · Health Care

$3.33as of 10/16/2026

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 1, 2026

SCNX Shares Drop 19% After Hours Amid Reverse Split. SCNX shares fell 19% in after‑hours trading after the company announced a reverse stock split. The reverse split will consolidate shares, potentially raising the share price but also reducing the number of shares outstanding. The drop comes while the stock sits near its 12‑month low and has a very low RSI, indicating a possible oversold condition. The reverse split may be a move to meet listing requirements and support future trading.

Active signals

Support level
$0.360625
Industry
Biotechnology: Pharmaceutical Preparations

What SCNX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume Spike31-14.5%29%
Bollinger Band Breakdown21-6.7%43%
Bollinger Band Breakout18+0.7%50%
200-Day Moving Average TouchActive now9-2.1%44%
Any 20-session window (baseline)-9.0%34%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About SCNX

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients w…

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Employees
4

Fundamentals

1-day range
$3.25$3.42
Market cap
$15.14M
P/E (trailing)
—
P/E (forward)
Infinity
EPS (trailing)
$-8.63
Dividend yield
—
Beta
3.24
Avg. volume
188.9K
Ex-dividend date
July 19, 2024
Dividend pay date
July 24, 2024
52-week range
$3.21$65

How Scienture Holdings Inc. Common Stock Makes Money

Where the revenue actually goes — FY2025 annual results

market-wall.comTotalRevenue$431.6KSG&A$7.93M (1836%)R&D$1.96M (453%)Cost of Revenue$100.1K (23%)SCNX

Source: 10-K filed Mar 30, 2026 · via SEC EDGAR / Finnhub

Gross Profit$331.5K(77%)
Operating Income-$42.59M(-9868%)

Forecasts

1 analyst ratings

Buy 86%
Hold 14%
Sell 0%
1-year price forecast
High
$37.5
+1026.1%
Median
$37.5
+1026.1%
Low
$37.5
+1026.1%

Scienture Holdings Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • SCNX
    Scienture Holdings Inc. Common Stock
    $3.36
    ▼ 0.59%
    Market cap $15.14MP/E —
    $3.21$65
  • HIND
    Vyome Holdings Inc. Common Stock
    $1.87
    ▼ 2.09%
    Market cap $15.02MP/E —
    $1.75$6.56
  • KTTA
    Pasithea Therapeutics Corp. Common Stock
    $0.42
    ▲ 2.44%
    Market cap $14.82MP/E —
    $0.281$2.06
  • TPST
    Tempest Therapeutics Inc. Common Stock
    $0.624
    ▼ 1.73%
    Market cap $14.42MP/E —
    $0.6801$12.23
  • BFRI
    Biofrontera Inc. Common Stock
    $0.822
    ▼ 2.95%
    Market cap $16.00MP/E —
    $0.555$1.66
  • KALA
    KALA BIO Inc. Common Stock
    $0.19
    ▼ 1.04%
    Market cap $14.25MP/E —
    $0.2593$95.5
  • COCP
    Cocrystal Pharma Inc. Common Stock
    $1.02
    ▼ 0.97%
    Market cap $14.20MP/E —
    $0.76$2.03

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Institutional Ownership

March 31, 2026

Total shares held
1.22M
Total value held
$324.7K
Institutional holders
13
Top holders this quarter
  • Unknown432.2K
  • Unknown408.1K
  • Unknown107.8K
  • Unknown84.2K
  • Unknown47.7K
  • Unknown44.8K
  • Unknown36.4K
  • Unknown27.6K
  • Unknown15.0K
  • Unknown13.9K

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.